** Morningstar says it is upbeat on Australia's Telix Pharmaceuticals after co reported FY24 revenue ahead of its own and brokerage's forecasts
** "Telix is broadly tracking our expectations and we leave our constant-currency forecasts broadly unchanged," says brokerage
** Morningstar raises fair value estimate on stock by 6% to A$18, largely on stronger U.S. dollar
** Seven of eight analysts rate the stock "buy" or higher, one "hold"; their median PT is A$23.80 – LSEG data
** Stock has gained 1.5% YTD, as of last close
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.